Page 257 - Haematologica Vol. 110 - January 2025

LETTER TO THE EDITOR
In conclusion, MAGE-A1 is an antigen expressed by a sub- set of MM patients associated with advanced disease and EMD. MAGE-A1-directed TCR-1367 therapy appears feasible for the tested dose in this patient group. Further clinical studies are required within the multi-refractory patient population, especially those relapsing after currently ap- proved T-cell redirecting therapies.
Authors
Josefine Krüger,1 Matthias Obenaus,1 Igor Wolfgang Blau,2 Dana Hoser,3 Martin Vaegler,4 Hana Rauschenbach,4 Ioannis Anagnostopoulos,5 Korinna Jöhrens,5 Vivian Scheuplein,6 Elisa Kieback,6 Judith Böhme,5 Ann-Christin von Brünneck,5 Jan Krönke,1,7 Antonia Busse,1,6,7 Gerald Willimsky,3,7,8 Thomas Blankenstein,6 Antonio Pezzutto,1,6 Ulrich Keller1,6,7 and Axel Nogai1
1Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, Berlin; 2Department of Hematology, Oncology and Cancer Immunology, Campus Virchow Klinikum, Charité- Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin; 3Institute of Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin; 4Experimental and Clinical Research Center, Zellkulturlabor für Klinische Prüfung ZKP, Charité- Universitätsmedizin Berlin, Campus Berlin Buch, Berlin; 5Institute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin; 6Max-Delbrück-Center for Molecular Medicine, Berlin; 7German Cancer Consortium (DKTK), partner site Berlin, a partnership between German Cancer Research Center (DKFZ) and Charité- Universitätsmedizin Berlin, Berlin and 8German Cancer Research Center (DKFZ), Heidelberg, Germany
Correspondence:
A. NOGAI - nogai@onkologie-tiergarten.de U. KELLER - ulrich.keller@charite.de
https://doi.org/10.3324/haematol.2024.286124
References
1. Yang P, Meng M, Zhou Q. Oncogenic cancer/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188558.
2. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254(5038):1643-1647.
3. Dhodapkar MV, Osman K, Teruya-Feldstein J, et al. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4,
Received: June 28, 2024. Accepted: September 2, 2024. Early view: September 12, 2024.
©2025 Ferrata Storti Foundation Published under a CC BY-NC license
Disclosures
AN discloses consultancy for Celgene, Janssen, Roche, Takeda, Alexion, Sanofi, GSK and BMS and receives research funding from BMS, Janssen and Celgene. VS, EK and DH are full-time employees of T-knife Therapeutics Inc. TB and EK are shareholders in T-knife Therapeutics Inc. TB is a founder and scientific advisory board member of T-knife Therapeutics. MO and TB are inventors of a patent applied by the Max-Delbrück Center describing the TCR used in this study. The remaining authors have non conflicts of interest to disclose.
Contributions
JK collected and analyzed the IHC expression data and created the graphs. IA, KJ, JB and A-CB provided the immunohistochemistry slides of MAGE-A1 expression. MO, AP, TB, UK, J K, IWB, AB and AN designed the study. MO, DH, VS, GW, TB and AP contributed the preliminary work for TCR-1367 and designed the manufacturing process with MV and HR. MV and HR manufactured the TCR-1367 T cells. MO, TB, AP, VS and EK designed the clinical trial. JK and AN wrote the manuscript. All authors revised the manuscript and approved the final version which was submitted.
Acknowledgments
The protocol for determining the vector copy number for pharmacokinetics analysis by qPCR was kindly provided by Dr. Michael Rothe, Hannover Medical School, Hannover, Germany. The sponsor of the trial was Charité-Universitätsmedizin Berlin.
Funding
The clinical trial received funding from the German Federal Ministry of Education and Research (BMBF) (to TB an AP) in the context of the program “Personalized Medicine”.
Data-sharing statement
Reasonable requests for further data will be considered. Requests should be directed to the corresponding authors.
CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun. 2003;3:9.
4. Chari A, Cho HJ, Dhadwal A, et al. A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. Blood Adv. 2017;1(19):1575-1583.
5. Holstein SA, Grant SJ, Wildes TM. Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future. J Clin Oncol. 2023;41(27):4416-4429.
Haematologica | 110 January 2025
249